Get this special report here! This expert analysis from “The Gold Sheet,” the best and only resource dedicated to international QA/QC compliance, has already been featured on CNN Money and Fierce Pharma. Now you can get the entire report for just $195! This report covers the torrent of warning letters, important alerts and other FDA action since the Obama administration took over, and outlines the probable future.
This report is exclusively from “The Gold Sheet,” the resource that helps you face the bigger, faster, tougher ERA with confidence.
Special offer from the publisher of “The Gold Sheet:”
- Special Report only: 2010 Report on Drug GMP Recalls and Warning Letters for just $195.
- SPECIAL OFFER: A full year of "The Gold Sheet" (12 print issues) for 20% off the regular price, a full $195 off, and also get this Special Report at no additional cost.
- BONUS: Your subscription will include online access to a rolling 90 days of archive content!
- DOUBLE BONUS: Your subscription also includes COMPLIMENTARY email updates with the latest breaking news!
- BONUS UPGRADE: You can upgrade your "Gold Sheet" subscription to include a full 365 days of online access for just $195 — another $100 off the regular price. Get it HERE.
|
Offer ends November 31, 2010.
* Offer available for new subscriptions only and may not be combined with any other offers.
|
|
$195 - Purchase this Special Report with a credit card from our secure
Web site and get
immediate download of
“2010 Report on Drug GMP Recalls and Warning Letters.”

|
| Best Offer: Get
this Bonus Report FREE when you subscribe to "The Gold
Sheet" at the
substantially discounted rates
below: |
|
$780 - purchase your
"Gold Sheet" subscription today and get 90 day rolling archive access and get
your Bonus Report “2010 Report on Drug GMP Recalls and Warning Letters.” -FREE!

$975 - purchase your "Gold Sheet" subscription today and get 365 day rolling archive access and get
your Bonus Report “2010 Report on Drug GMP Recalls and Warning Letters.” -FREE!

|
Get all this from “The Gold Sheet” …
- Analysis of developments in FDA regulations and policies
- State-of-the-art production and quality techniques
- Trends in quality control practices
- Best practices in supply chain integrity
- In-depth reports on a vast range of GMP issues, such as sterility, microbial controls, validation, laboratory data integrity, cross-contamination, out-of-spec (OOS) results and stability testing
- Drug recall and warning letter data
- Early warning of new directions in FDA enforcement policy
- Insights from peers on ensuring quality from contract suppliers and service providers
To help you …
- Stay on track no matter how fast things change
- Steer your own course around common pitfalls
- Understand how policy-makers and regulators think
- React quickly to surprises and problems
|
|